Ex Vivo Expanded 3D Human Kidney Spheres Engraft Long Term and Repair Chronic Renal Injury in Mice.
Sign Up to like & getrecommendations! Published in 2020 at "Cell reports"
DOI: 10.1016/j.celrep.2019.12.047
Abstract: End-stage renal disease is a worldwide epidemic requiring renal replacement therapy. Harvesting tissue from failing kidneys and autotransplantation of tissue progenitors could theoretically delay the need for dialysis. Here we use healthy and end-stage human… read more here.
Keywords: kidney; long term; vivo expanded; mice ... See more keywords
Potent antitumor efficacy of ex vivo expanded and cryopreserved human natural killer cells against orthotopic pancreatic cancer
Sign Up to like & getrecommendations! Published in 2019 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2019.03.361
Abstract: Background & Aim Natural killer (NK) cells are specialized components of the innate immune system that contribute to the first line of defense against viral infections and cancer. Ex vivo expanded NK cells are a… read more here.
Keywords: efficacy; cancer; vivo expanded; expanded cryopreserved ... See more keywords
Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Sign Up to like & getrecommendations! Published in 2020 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2020.09.010
Abstract: Engagement between the natural killer group 2, member D (NKG2D) receptor and its ligands is one of the main mechanisms used by immune cells to target stressed cells for cell death. NKG2D ligands are known… read more here.
Keywords: cell; bortezomib; nkg2d ligand; vivo expanded ... See more keywords
A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants
Sign Up to like & getrecommendations! Published in 2018 at "Scientific Reports"
DOI: 10.1038/s41598-018-25574-7
Abstract: There is considerable interest in therapeutic transfer of regulatory T cells (Tregs) for controlling aberrant immune responses. Initial clinical trials have shown the safety of Tregs in hematopoietic stem cell transplant recipients and subjects with… read more here.
Keywords: trial; donor kidney; regulatory cells; vivo expanded ... See more keywords
Ex-Vivo Expanded NK Cell Therapy Combined with Elotuzumab for MRD after Autologous Stem Cell Transplantation: A Phase I/ II Clinical Trial in Progress
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-127739
Abstract: Recent advances of monoclonal antibodies provide a potent anti-myeloma effect based on antibody-dependent cytotoxicity (ADCC). Elotuzumab is a monoclonal antibody which binds SLAMF7 on the surface of myeloma cells and induces ADCC by NK cells… read more here.
Keywords: clinical trial; phase; trial; vivo expanded ... See more keywords
Extracellular Vesicles Derived From Ex Vivo Expanded Regulatory T Cells Modulate In Vitro and In Vivo Inflammation
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.875825
Abstract: Extracellular vehicles (EVs) are efficient biomarkers of disease and participate in disease pathogenesis; however, their use as clinical therapies to modify disease outcomes remains to be determined. Cell-based immune therapies, including regulatory T cells (Tregs),… read more here.
Keywords: vitro vivo; inflammation; regulatory cells; inflammatory ... See more keywords
Carfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapy.
Sign Up to like & getrecommendations! Published in 2018 at "Neoplasma"
DOI: 10.4149/neo_2018_171019n668
Abstract: Natural killer (NK) cell-based immunotherapy is promising, as NK cells are in the first line of defense against cancer and capital of lysing tumor cells without pre-stimulation. However, NK cells from multiple myeloma (MM) patients… read more here.
Keywords: patient autologous; natural killer; vivo expanded; cell ... See more keywords